Immunologic criteria are poor predictors of virologic outcome: Implications for HIV treatment monitoring in resource-limited settings

Clinical Infectious Diseases

Volumn 53, Issue 12, 2011, Pages 1283-1290

  Rawizza, Holly E ^a   Chaplin, Beth ^b   Meloni, Seema T ^b   Eisen, Geoffrey ^b   Rao, Tara ^b   Sankalé, Jean Louis ^b   Dieng Sarr, Abdoulaye ^b   Agbaji, Oche ^c   Onwujekwe, Daniel I ^d   Gashau, Wadzani ^e   Nkado, Reuben ^f   Ekong, Ernest ^g   Okonkwo, Prosper ^g   Murphy, Robert L ^h   Kanki, Phyllis J ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF JOS   (Nigeria)

^d NIGERIAN INSTITUTE OF MEDICAL RESEARCH   (Nigeria)

^e UNIVERSITY OF MAIDUGURI   (Nigeria)

^f Military Hospital   (Nigeria)

^g APIN PUBLIC HEALTH INITIATIVES   (Nigeria)

^h NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BIOLOGICAL MONITORING; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL PARAMETERS; MAJOR CLINICAL STUDY; MALE; NIGERIA; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT FAILURE; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; NIGERIA; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 81855172463     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir729     Document Type: Article

References (31)

1. WHO/UNAIDS/UNICEF. Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2010. Geneva, Switzerland: WHO Press; 2010.
2. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA Panel. JAMA 2010; 304:321-33.
3. Clumeck N, Monforte A, Gatell J, Battegay M, et al. The EACS Executive Committee. Clinical management and treatment of HIV infected adults in Europe. EACS guidelines. 2011; Version 5-4. www.europeanaidsclinicalsociety.org/. Accessed 18 July 2011.
4. Hornberger J, Holodniy M, Robertus K, et al. A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy. Med Decis Making 2007; 27:789-821. (Pubitemid 350136010)
5. Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD41 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54. (Pubitemid 27255797)
6. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD41 lymphocyte counts and the risk of progression to AIDS. New Engl J Med 1996; 334:426-31. (Pubitemid 26055842)
7. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomized non-inferiority trial. Lancet 2010; 375:123-31.
8. Phillips A, Van Oosterhout J. DART points way for HIV treatment programmes. Lancet 2010; 375:96-8.
9. Smith DM, Schooley RT. Running with scissors: using antiretroviral therapy without monitoring viral load. Clin Infect Dis 2008; 46: 1598-600. (Pubitemid 351706743)
10. Calmy A, Ford N, Hirschel B, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007; 44:128-34. (Pubitemid 44968997)
11. Petti CA, Polage CR, Quinn TC, et al. Laboratory medicine in Africa: a barrier to effective health care. Clin Infect Dis 2006; 42:377-82. (Pubitemid 43122314)
12. Mee P, Fielding KL, Charalambous S, et al. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22:1971-7.
13. Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009; 23:697-700.
14. Moore DM, Awor A, Downing R, et al. CD41 T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 49:477-84.
15. Moore DM, Mermin J, Awor A, et al. Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr 2006; 43:436-9. (Pubitemid 44737101)
16. Federal Ministry of Health. National guidelines for HIV and AIDS treatment and care in adolescents and adults. Abuja, Nigeria, 2007. Available at: http://www.aidstar-one.com/national-guideline-or-hiv-and-aids-treatmentand- ca.
17. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. Available at: http://www.who.int/hiv/pub/arv/adult2010/en/. Accessed 3 August 2011.
18. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003; 17: 1369-75. (Pubitemid 36819851)
19. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-95. (Pubitemid 38553709)
20. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353:863-8. (Pubitemid 29126872)
21. Lohse N, Kronborg G, Gerstoft J, et al. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, populationbased, 6-year follow-up study. Clin Infect Dis 2006; 42:136-44. (Pubitemid 41832093)
22. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, et al. Options for second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447-52. (Pubitemid 46147631)
23. Gallant JE. Drug resistance after failure of initial antiretroviral therapy in resource-limited countries. Clin Infect Dis 2007; 44:453-5. (Pubitemid 46147632)
24. Soria A, Porten K, Fampou-Toundji J, et al. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. Antivir Ther 2009; 14:339-47.
25. Flandre P, Descamps D, Joly V, et al. A survival method to estimate the time to occurrence of mutations: an application to thymidine analogue mutations in HIV-1-infected patients. J Infect Dis 2004; 189:862-70. (Pubitemid 38328188)
26. Goetz MB, Ferguson MR, Han X, et al. Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure. J Acquir Immune Defic Syndr 2006; 43:541-9. (Pubitemid 44885620)
27. Cozzi-Lepri A, Phillips AN, Ruiz L, et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 2007; 21:721-32. (Pubitemid 46568629)
28. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infection patients in DUET-1: 24-week results from a randomized, double-blind, placebocontrolled trial. Lancet 2007; 370:29-38. (Pubitemid 47017466)
29. Lazzarin A, Campbell T, Clotet , et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infection patients in DUET-2: 24-week results from a randomized, double-blind, placebocontrolled trial. Lancet 2007; 370:39-48. (Pubitemid 47017467)
30. Taiwo B, Chaplin B, Penugonda S, et al. Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1. Curr HIV Res 2010; 8:194-8.
31. Gupta R, Hill A, Sawyer AW, et al. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47:712-22.